Praxis Precision posts $925M year-end cash balance

Praxis Precision Medicines reported preliminary year-end liquidity, stating that as of December 31, 2025 its cash, cash equivalents and marketable securities totaled approximately $925 million.

Rhea-AI Filing Summary

Praxis Precision Medicines reported preliminary year-end liquidity, stating that as of December 31, 2025 its cash, cash equivalents and marketable securities totaled approximately $925 million. This figure is based on unaudited internal information and management estimates for the year and is still subject to the company’s normal year-end closing procedures.

The company emphasized that its independent registered public accounting firm has not audited or reviewed this estimate and does not provide any assurance on it. The disclosure is being furnished rather than filed, meaning it is provided for investor information but is not automatically incorporated into other securities law filings unless specifically referenced.

Insights

Equity research analyst

Praxis discloses a large, unaudited $925M year-end cash balance.

Praxis Precision Medicines indicates that as of December 31, 2025 it held approximately $925 million in cash, cash equivalents and marketable securities. This gives a snapshot of the company’s liquidity position at year-end, although the excerpt does not compare this level to prior periods or specific funding needs.

The company notes that this amount is a preliminary management estimate, based on unaudited information and subject to its financial closing procedures and a subsequent audit. That language underscores that the figure could change once final results for the year ended December 31, 2025 are completed and reviewed.

The disclosure frames the number as being “furnished” rather than “filed,” which limits how it is incorporated into other regulatory documents. Future annual or quarterly reports covering the period ended December 31, 2025 are expected to provide audited numbers that will clarify the final cash, cash equivalents and marketable securities balance.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What cash balance did Praxis Precision Medicines (PRAX) report as of December 31, 2025?

Praxis Precision Medicines reported that as of December 31, 2025, its cash, cash equivalents and marketable securities were approximately $925 million based on preliminary estimates.

Is the $925 million cash figure for PRAX audited?

No. The approximately $925 million in cash, cash equivalents and marketable securities is based on preliminary unaudited information and management estimates and remains subject to financial closing procedures and audit.

Does the Praxis Precision Medicines 8-K provide full 2025 financial results?

No. The 8-K only furnishes a preliminary estimate of cash, cash equivalents and marketable securities as of December 31, 2025 and is not a comprehensive statement of financial results for the year.

How is the liquidity disclosure for PRAX treated under securities laws?

The company states that the information in this item is being furnished and not filed, so it is not automatically subject to Section 18 liability or incorporated into other filings unless specifically referenced.

What risks or uncertainties are associated with PRAX’s preliminary cash estimate?

Praxis notes that the preliminary estimate may change due to financial closing procedures, the upcoming audit by its independent registered public accounting firm, and other risks described in its prior SEC reports.

What forward-looking statements does PRAX include in this liquidity update?

The company includes forward-looking statements regarding its future expectations, plans and prospects, including the preliminary cash estimate, and cautions that these are subject to risks and uncertainties outlined in its Form 10-K for 2024, Form 10-Q for the quarter ended June 30, 2025 and other filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/06/2026 - 04:24 PM Learn about SEC filing dates

FALSE000168954800016895482026-01-062026-01-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 6, 2026

PRAXIS PRECISION MEDICINES, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-39620			47-5195942
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

Praxis Precision Medicines, Inc.

99 High Street, 30th Floor

Boston, Massachusetts 02110

(Address of principal executive offices, including zip code)

(617) 300-8460

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trade Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

PRAX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02. Results of Operations and Financial Condition.

Praxis Precision Medicines, Inc. (the “Company”) is providing the following financial information. As of December 31, 2025, the Company’s cash, cash equivalents and marketable securities were approximately $925 million.

The cash, cash equivalents and marketable securities information above is based on preliminary unaudited information and management estimates for the year ended December 31, 2025, is not a comprehensive statement of the Company’s financial results as of and for the fiscal year ended December 31, 2025, and is subject to completion of the Company’s financial closing procedures. The Company’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, this preliminary estimate.

The information contained in this item is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward-Looking Statements

This Current Report on Form 8-K (the “Current Report”) contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding the Company’s future expectations, plans and prospects, including, without limitation, statements regarding the preliminary estimate of the Company’s cash, cash equivalents and marketable securities as of December 31, 2025, as well as other statements that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995.

The forward-looking statements included in this Current Report are subject to a number of risks, uncertainties and assumptions, including, without limitation, potential adjustments as a result of the Company’s financial closing procedures and the audit to be conducted by the Company’s independent registered accounting firm and other risks as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 and its other filings with the Securities and Exchange Commission. These statements are based only on facts currently known by the Company and speak only as of the date of this Current Report. As a result, you are cautioned not to rely on these forward-looking statements and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PRAXIS PRECISION MEDICINES, INC.
Date: January 6, 2026			By:						/s/ Marcio Souza
									Marcio Souza
									Chief Executive Officer